Short-term neurotoxicity trajectory in patients with thoracic cancers receiving triweekly albumin-bound paclitaxel.

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2026-03-12 DOI:10.1080/1120009X.2026.2630448

Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng

{"title":"Short-term neurotoxicity trajectory in patients with thoracic cancers receiving triweekly albumin-bound paclitaxel.","authors":"Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng","doi":"10.1080/1120009X.2026.2630448","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to investigate the short-term trajectory of peripheral neuropathy in patients receiving triweekly albumin-bound paclitaxel (nab-paclitaxel) chemotherapy. 235 patients were recruited from March to August 2024, of whom 65.1% developed neuropathy. Peripheral neuropathy was assessed at baseline (the first day of chemotherapy) and on days 3, 7, 14, and 21. Group-based trajectory modeling was used to identify two distinct trajectories of neuropathy: a rise-then-decline group and a gradual-increase group. Multivariable logistic regression revealed that patients with an increased cumulative dose (per 200 mg increment: odds ratio [OR] = 1.52; 95% confidence interval [CI]: 1.28-1.78), anemia (OR = 2.68; 95% CI: 1.30-5.52), and age < 60 years (OR = 2.17; 95% CI: 1.03-4.60) were more likely to belong to the rise-then-decline trajectory group. Clinicians should closely monitor symptom severity between 7 and 14 days post-chemotherapy. In older patients, combining patient-reported outcomes with clinical functional assessments may help detect subtle sensory neuropathic changes.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2026.2630448","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to investigate the short-term trajectory of peripheral neuropathy in patients receiving triweekly albumin-bound paclitaxel (nab-paclitaxel) chemotherapy. 235 patients were recruited from March to August 2024, of whom 65.1% developed neuropathy. Peripheral neuropathy was assessed at baseline (the first day of chemotherapy) and on days 3, 7, 14, and 21. Group-based trajectory modeling was used to identify two distinct trajectories of neuropathy: a rise-then-decline group and a gradual-increase group. Multivariable logistic regression revealed that patients with an increased cumulative dose (per 200 mg increment: odds ratio [OR] = 1.52; 95% confidence interval [CI]: 1.28-1.78), anemia (OR = 2.68; 95% CI: 1.30-5.52), and age < 60 years (OR = 2.17; 95% CI: 1.03-4.60) were more likely to belong to the rise-then-decline trajectory group. Clinicians should closely monitor symptom severity between 7 and 14 days post-chemotherapy. In older patients, combining patient-reported outcomes with clinical functional assessments may help detect subtle sensory neuropathic changes.

查看原文本刊更多论文

每三周接受白蛋白结合紫杉醇治疗的胸部癌症患者的短期神经毒性轨迹。

本研究旨在探讨接受三周白蛋白结合紫杉醇（nab-paclitaxel）化疗的患者周围神经病变的短期轨迹。2024年3月至8月招募235例患者，其中65.1%发生神经病变。周围神经病变在基线（化疗第一天）和第3、7、14和21天进行评估。使用基于组的轨迹建模来确定两种不同的神经病变轨迹：先上升后下降组和逐渐增加组。多变量logistic回归显示，累积剂量增加（每增加200 mg：优势比[OR] = 1.52； 95%可信区间[CI]: 1.28-1.78）、贫血（OR = 2.68; 95% CI: 1.30-5.52）和年龄< 60岁（OR = 2.17; 95% CI: 1.03-4.60）的患者更有可能属于先上升后下降的轨迹组。临床医生应密切监测化疗后7至14天的症状严重程度。在老年患者中，将患者报告的结果与临床功能评估相结合可能有助于发现细微的感觉神经性病变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.